51IN - Genomics in renal cancer: From science to clinical practice
|Date||29 September 2012|
|Event||ESMO Congress 2012|
|Session||Molecular answers and targets on the horizon for the treatment of GU malignancies|
|Topics|| Renal Cell Cancer
|Presenter||Bin Tean Teh|
Approximately 290,000 new cases of renal cell carcinoma (RCC) are diagnosed each year worldwide and 102,000 deaths. It is a morphologically, and genetically heterogenous disease with distinct underlying molecular mechanisms in each subtype. In this lecture, the evidence of this molecular heterogeneity with more recent discoveries will be presented and discussed. For example, we have recently identified the frequent mutations of PBRM1, a member of the SWI-SNF complex, in clear cell RCC (the most common type of RCC) and a lesser degree of mutations in a group of histone modifiers. This has opened up a new field of investigations, from basic biology to clinical implications. In addition, we also demonstrated the involvement of LRRK2, a gene associated with early-onset Parkinson's disease, in papillary type 1 RCC (second most common type of RCC) and its interaction with c-MET, a gene that has been previously implied in this subtype of tumors. We have also recently discovered a novel metabolic pathway that is integral to the tumorigenesis of papillary type II (an aggressive type of papillary tumor). All these present new opportunities for further investigations to establish their biological and therapeutic roles in RCC.Disclosure
The author has declared no conflicts of interest.